演題詳細

一般口演 / Oral Session

一般口演 99 (Oral Session 99) :ATL:臨床・病理

print

日程
2013年10月13日(日)
時間
16:00 - 17:00
会場
第7会場 / Room No.7 (ロイトン札幌 2F リージェント)
座長・司会
宇都宮 與 (Atae Utsunomiya):1
1:今村病院分院 血液内科
 
前へ戻る

Clinical features and treatment outcomes of adult T-cell leukemia/lymphoma in Miyazaki prefecture

演題番号 : OS-3-141

上運天 綾子 (Ayako Kamiunten):1、関根 雅明 (Masaaki Sekine):1、亀田 拓郎 (Takuro Kameda):1、幣 光太郎 (Kotaro Shide):1、下田 晴子 (Haruko Shimoda):1、日高 智徳 (Tomonori Hidaka):1、久冨木 庸子 (Yoko Kubuki):1、北中 明 (Akira Kitanaka):1、下田 和哉 (Kazuya Shimoda):1

1:2nd Dept. Int. Med.,Miyazaki Univ.,Japan

 

Background: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive peripheral T cell neoplasm caused by human T-cell lymphotropic virus type I.
Patients and methods: To elucidate the clinical characteristics and outcome of ATLL patients, we retrospectively analyzed patients with ATLL in Miyazaki prefecture for the last 3 years. There were 77males and 53 females. The median age of the patients was 70 years (range 44–92). Subtypes included acute (n = 83), lymphoma (n = 30), and chronic (n = 8). Ninety-two patients were treated with combination chemotherapy (LSG15 (VCAP-AMP-VECP) or CHOP-based regimen).
Results: The median survival time for the patients who received combination chemotherapy was 10 months. Among these patients, median survival of patients 70 years and less and patients older than 70 years were 11.7 and 5.7 months, respectively (p=0.04). The median survival among all age groups for acute type and lymphoma type were 9.2 and 9.9 months, respectively.
Conclusion: The median survival time of patients 70 years and less in the daily practice in Miyazaki prefecture was similar to that reported in the clinical trials. The shorter survival in patients older than 70 years suggests that alternative therapeutic strategies for elderly patients are warranted.

前へ戻る